Vaccination against galectin-1 promotes cytotoxic T-cell infiltration in melanoma and reduces tumor burden
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Vaccination against galectin-1 promotes cytotoxic T-cell infiltration in melanoma and reduces tumor burden
Authors
Keywords
-
Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-01-12
DOI
10.1007/s00262-021-03139-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Anti-angiogenic agents — overcoming tumour endothelial cell anergy and improving immunotherapy outcomes
- (2021) Zowi R. Huinen et al. Nature Reviews Clinical Oncology
- Galectin-1–driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance
- (2019) Dhanya K. Nambiar et al. JOURNAL OF CLINICAL INVESTIGATION
- Development of a novel therapeutic vaccine carrier that sustains high antibody titers against several targets simultaneously
- (2017) Falk Saupe et al. FASEB JOURNAL
- A key role for galectin-1 in sprouting angiogenesis revealed by novel rationally designed antibodies
- (2016) Judy R. van Beijnum et al. INTERNATIONAL JOURNAL OF CANCER
- Shaping the Immune Landscape in Cancer by Galectin-Driven Regulatory Pathways
- (2016) Gabriel A. Rabinovich et al. JOURNAL OF MOLECULAR BIOLOGY
- Galectin expression in cancer diagnosis and prognosis: A systematic review
- (2015) Victor L. Thijssen et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Vaccines targeting self-antigens: mechanisms and efficacy-determining parameters
- (2015) Falk Saupe et al. FASEB JOURNAL
- Therapeutic vaccination against fibronectin ED-A attenuates progression of metastatic breast cancer
- (2015) Julia Femel et al. Oncotarget
- Galectin-1 induces vascular permeability through the neuropilin-1/vascular endothelial growth factor receptor-1 complex
- (2014) Ming-Heng Wu et al. ANGIOGENESIS
- Glycosylation-Dependent Lectin-Receptor Interactions Preserve Angiogenesis in Anti-VEGF Refractory Tumors
- (2014) Diego O. Croci et al. CELL
- Vascular galectins: Regulators of tumor progression and targets for cancer therapy
- (2013) Victor L. Thijssen et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Glioma-derived galectin-1 regulates innate and adaptive antitumor immunity
- (2013) Tina Verschuere et al. INTERNATIONAL JOURNAL OF CANCER
- Interfering with Gal-1-mediated angiogenesis contributes to the pathogenesis of preeclampsia
- (2013) N. Freitag et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Galectin-1 inhibits the viability, proliferation, and Th1 cytokine production of nonmalignant T cells in patients with leukemic cutaneous T-cell lymphoma
- (2012) F. Cedeno-Laurent et al. BLOOD
- Targeting Galectin-1 Overcomes Breast Cancer-Associated Immunosuppression and Prevents Metastatic Disease
- (2012) T. Dalotto-Moreno et al. CANCER RESEARCH
- A Unique Galectin Signature in Human Prostate Cancer Progression Suggests Galectin-1 as a Key Target for Treatment of Advanced Disease
- (2012) D. J. Laderach et al. CANCER RESEARCH
- Galectin-1 confers immune privilege to human trophoblast: implications in recurrent fetal loss
- (2012) R. E. Ramhorst et al. GLYCOBIOLOGY
- Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi’s sarcoma
- (2012) Diego O. Croci et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Why do human B cells secrete granzyme B? Insights into a novel B-cell differentiation pathway
- (2012) Magdalena Hagn et al. OncoImmunology
- Enhancement of T-cell-Mediated Antitumor Response: Angiostatic Adjuvant to Immunotherapy against Cancer
- (2011) R. P. M. Dings et al. CLINICAL CANCER RESEARCH
- The non-toxic and biodegradable adjuvant Montanide ISA 720/CpG can replace Freund's in a cancer vaccine targeting ED-B—a prerequisite for clinical development
- (2011) Elisabeth J.M. Huijbers et al. VACCINE
- Tumor Cells Secrete Galectin-1 to Enhance Endothelial Cell Activity
- (2010) V. L. Thijssen et al. CANCER RESEARCH
- Costly Cancer Drugs Trigger Proposals To Modify Clinical Trial Design
- (2009) C. Schmidt JNCI-Journal of the National Cancer Institute
- Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10
- (2009) Juan M Ilarregui et al. NATURE IMMUNOLOGY
- Identification of potent biodegradable adjuvants that efficiently break self-tolerance—A key issue in the development of therapeutic vaccines
- (2009) Maria Ringvall et al. VACCINE
- Loading doses for costly cancer biologicals: A cause for concern or tilting at windmills?
- (2008) Ivo M. Hennig et al. EUROPEAN JOURNAL OF CANCER
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started